Disclosures: Loghman Salimzadeh: Nothing to Disclose, Stuti Shah: Nothing to Disclose, Danie La: Nothing to Disclose, Hilario Ramos: Bluejay Therapeutics: Employee, Bluejay Therapeutics: Stock privately held company, Nancy Shulman: Bluejay Therapeutics, INC: Salary and equity, Hassan Javanbakht: Nothing to Disclose, Adam Gehring: Nothing to Disclose 452 PRECLINICAL PHARMACOKINETICS OF EDP-514, AN ORAL, ONCE-DAILY ANTIVIRAL TREATMENT FOR HEPATITIS B VIRUS Meng Huang 1 Khanh Hoang 1 Jonathan Kibel 1 Shucha Zhang 1 Lisha Xu 1 Yang Li 1 Indy Zang 1 Daniel Leonard 1 Siu-Lung Chan 1 Joshua Klaene 1 Yat Sun Or 1 Li-Juan Jiang 1 , 1 Enanta Pharmaceuticals Background: Hepatitis B virus (HBV) is a global public health threat that causes approximately 1.5 million new infections every year
Following the FDA approval of GLP-1 receptor agonists for sleep apnea treatment, Wesper is working with hospitals and physicians to bridge the gap between obesity, diabetes, GLP-1 medications , and sleep apnea
A circumference greater than 40 inches in men, or 35 in inches in women is a rough indicator
Mortality rate was significantly lower in the GLP-1RAs group (HR 0.62
Clear, colorless urine may actually indicate overhydration and potential electrolyte dilution
.webp)
